Next Generation Pathogen Sequencing for Prediction of Adverse Events

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03226158

Recruitment Status : Active, not recruiting

First Posted : July 21, 2017

Last Update Posted : May 6, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Karius, Inc.

Information provided by (Responsible Party):

St. Jude Children's Research Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	March 1, 2022
Estimated Study Completion Date :	May 1, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, Hollemon D, Natarajan S, Mahmud O, Kuenzinger W, Youssef S, Brenner A, Maron G, Choi J, Rubnitz JE, Sun Y, Tang L, Wolf J, Gawad C. Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. JAMA Oncol. 2020 Apr 1;6(4):552-556. doi: 10.1001/jamaoncol.2019.4120. Erratum In: JAMA Oncol. 2020 Feb 27;:

To Top